EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A US-based national surveillance study for the susceptibility and epidemiology of Clostridioides difficile isolates with special reference to ridinilazole: 2020–2021

D R Snydman iD, L A McDermott iD, C M Thorpe, E J C Goldstein, A N Schuetz, S Johnson, D N Gerding, L Gluck, D Bourdas, K C Carroll, C K Lancaster, K W Garey und 3 weitere

Antimicrobial Agents and Chemotherapy · 18.10.2023 · 67 (10)

DOI: 10.1128/aac.00349-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 18.10.2023. Verfasst von D R Snydman und 14 weiteren Autor:innen. Beteiligte Einrichtung: Tufts Medical Center , Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Clostridioides difficile, Clostridium Infections. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Summit Therapeutics, LLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We have previously reported on the susceptibility and epidemiology of Clostridioides difficile isolates from six geographically dispersed medical centers in the United States. This current survey was conducted with isolates collected in 2020–2021 from six geographically dispersed medical centers in the United States, with specific attention to susceptibility to ridinilazole as well as nine comparators. C. difficile isolates or stools from patients with C. difficile antibiotic-associated diarrhea were collected and referred to a central laboratory. After species confirmation of 300 isolates at the central laboratory, antibiotic susceptibilities were determined by the agar dilution method [M11-A9, Clinical and Laboratory Standards Institute (CLSI)] against the 10 agents. Ribotyping was performed by PCR capillary gel electrophoresis on all isolates. Ridinilazole had a minimum inhibitory concentration (MIC) 90 of 0.25 mcg/mL, and no isolate had an MIC greater than 0.5 mcg/mL. In comparison, fidaxomicin had an MIC 90 of 0.5 mcg/mL. The vancomycin MIC 90 was 2 mcg/mL with a 0.7% resistance rate [both CLSI and European Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria]. The metronidazole MIC 90 was 1 mcg/mL, with none resistant by CLSI criteria, and a 0.3% resistance rate by EUCAST criteria. Among the 50 different ribotypes isolated in the survey, the most common ribotype was 014–020 (14.0%) followed by 106 (10.3%), 027 (10%), 002 (8%), and 078–126 (4.3%). Ridinilazole maintained activity against all ribotypes and all strains resistant to any other agent tested. Ridinilazole showed excellent in vitro activity against C. difficile isolates collected between 2020 and 2021 in the United States, independent of ribotype.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clostridioides difficileClostridium InfectionsHumansAnti-Bacterial AgentsClostridioidesMicrobial Sensitivity TestsRibotypingBenzimidazolesPyridines

Stichwörter der Autor:innen

Clostridioides difficileUS surveillance studiesin vitro activityribotypingridinilazole

Substanzen

Anti-Bacterial AgentsridinilazoleBenzimidazolesPyridines

Autor:innen und Institutionen

  • Tufts Medical Center , Boston, Massachusetts, USA.
  • Tufts University School of Medicine and the Stuart B. Levy Center for the Integrated Management of Antimicrobial Resistance , Boston, Massachusetts, USA.
  • Kindred Health Care System , Rancho Cucamonga, California, USA.
  • Mayo Clinic School of Medicine and Science , Rochester, Minnesota, USA.
  • Edward Hines, Jr. VA Hospital , Hines, Illinois, USA.
  • Loyola University Medical Center , Maywood, Illinois, USA.

ORCID-Profile: D R Snydman, L A McDermott

Förderung

  • Summit Therapeutics, LLC

Zitieren

APA

Snydman, D. R., McDermott, L. A., Thorpe, C. M., Goldstein, E. J. C., Schuetz, A. N., Johnson, S., Gerding, D. N., Gluck, L., Bourdas, D., Carroll, K. C., Lancaster, C. K., Garey, K. W., Wang, Q., Walk, S. T., & Duperchy, E. (2023). A US-based national surveillance study for the susceptibility and epidemiology of Clostridioides difficile isolates with special reference to ridinilazole: 2020–2021. Antimicrobial Agents and Chemotherapy, 67(10). https://doi.org/10.1128/aac.00349-23

Vancouver

Snydman DR, McDermott LA, Thorpe CM, Goldstein EJC, Schuetz AN, Johnson S, et al. A US-based national surveillance study for the susceptibility and epidemiology of Clostridioides difficile isolates with special reference to ridinilazole: 2020–2021. Antimicrobial Agents and Chemotherapy. 2023;67(10). doi:10.1128/aac.00349-23

BibTeX
@article{Snydman2023,
  author = {Snydman, D R and McDermott, L A and Thorpe, C M and Goldstein, E J C and Schuetz, A N and Johnson, S and Gerding, D N and Gluck, L and Bourdas, D and Carroll, K C and Lancaster, C K and Garey, K W and Wang, Q and Walk, S T and Duperchy, E},
  title = {A US-based national surveillance study for the susceptibility and epidemiology of Clostridioides difficile isolates with special reference to ridinilazole: 2020–2021},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2023},
  volume = {67},
  number = {10},
  doi = {10.1128/aac.00349-23}
}
Kostenlos starten →